Email: cspc@cspc.cn
Media
News Center
Apr. 29
2026
VOLUNTARY ANNOUNCEMENT - SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR AMPHOTERICIN B LIPOSOMAL, POWDER FOR CONCENTRATE FOR DISPERSION FOR INFUSION (HC1507G2) APPROVE
Apr. 23
VOLUNTARY ANNOUNCEMENT - APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Apr. 20
VOLUNTARY ANNOUNCEMENT - Phase Ib/III Clinical Study of Sirolimus for Injection (Albumin-Bound) (HB1901) for the Treatment of Advanced Malignant Perivascular Ep
Apr. 15
VOLUNTARY ANNOUNCEMENT - SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar. 31
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
